Literature DB >> 30126965

Deletion of One 23S rRNA Gene (rrl) Copy Contributes to the Development of Linezolid Resistance in Staphylococcus warneri.

Caroline Rouard1,2, Florence Doucet-Populaire3,2, Christelle Guillet-Caruba1, Millie Villet1, Nadège Bourgeois-Nicolaos1,2.   

Abstract

Entities:  

Keywords:  Staphylococcus warneri; coagulase-negative staphylococci; drug resistance mechanisms; linezolid; oxazolidinones; ribosomes

Mesh：

Substances：

Year:  2018        PMID： 30126965      PMCID： PMC6201131          DOI： 10.1128/AAC.01139-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  14 in total

1.  Linezolid penetration into osteo-articular tissues.

Authors:  B Rana; I Butcher; P Grigoris; C Murnaghan; R A Seaton; C M Tobin
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

2.  Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015).

Authors:  Michael A Pfaller; Rodrigo E Mendes; Jennifer M Streit; Patricia A Hogan; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

3.  Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo.

Authors:  Nadège Bourgeois-Nicolaos; Laurent Massias; Brigitte Couson; Marie-José Butel; Antoine Andremont; Florence Doucet-Populaire
Journal:  J Infect Dis       Date:  2007-04-03       Impact factor: 5.226

4.  Characterization of 26 Staphylococcus warneri isolates from orthopedic infections.

Authors:  Davide Campoccia; Lucio Montanaro; Livia Visai; Tolmino Corazzari; Claudio Poggio; Francesco Pegreffi; Alessandra Maso; Valter Pirini; Stefano Ravaioli; Ilaria Cangini; Pietro Speziale; Carla Renata Arciola
Journal:  Int J Artif Organs       Date:  2010-09       Impact factor: 1.595

5.  Mutation in the L3 Ribosomal Protein Could Be Associated with Risk of Selection of High-Level Linezolid-Resistant Staphylococcus epidermidis Strains.

Authors:  Caroline Rouard; Elisabeth Aslangul; Alexandre Rivière; Claire Deback; Marie-José Butel; Florence Doucet-Populaire; Nadège Bourgeois-Nicolaos
Journal:  Microb Drug Resist       Date:  2016-10-18       Impact factor: 3.431

6.  Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection.

Authors:  Wei Gao; Kyra Chua; John K Davies; Hayley J Newton; Torsten Seemann; Paul F Harrison; Natasha E Holmes; Hyun-Woo Rhee; Jong-In Hong; Elizabeth L Hartland; Timothy P Stinear; Benjamin P Howden
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

7.  rRNA Operon Copy Number Can Explain the Distinct Epidemiology of Hospital-Associated Methicillin-Resistant Staphylococcus aureus.

Authors:  A C Fluit; M D Jansen; T Bosch; W T M Jansen; L Schouls; M J Jonker; C H E Boel
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

8.  Septic arthritis due to Staphylococcus warneri: a diagnostic challenge.

Authors:  Barbara Legius; Kristel Van Landuyt; Patrick Verschueren; Rene Westhovens
Journal:  Open Rheumatol J       Date:  2012-11-02

9.  ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries.

Authors:  Michael A Pfaller; Rodrigo E Mendes; Jennifer M Streit; Patricia A Hogan; Robert K Flamm
Journal:  J Antimicrob Chemother       Date:  2017-11-01       Impact factor: 5.790

10.  Antibiotic sensitivities of coagulase-negative staphylococci and Staphylococcus aureus in hip and knee periprosthetic joint infections: does this differ if patients meet the International Consensus Meeting Criteria?

Authors:  Elena De Vecchi; David A George; Carlo L Romanò; Fabrizio E Pregliasco; Roberto Mattina; Lorenzo Drago
Journal:  Infect Drug Resist       Date:  2018-04-13       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.